LONDON--(BUSINESS WIRE)--MiNA Therapeutics Limited, the pioneer in small activating RNA (RNAa) therapeutics, highlights preclinical research presented by academic partners at the annual meeting of the ...
LONDON, June 12, 2025--(BUSINESS WIRE)--MiNA Therapeutics Limited, the pioneer in small activating RNA (RNAa) therapeutics, announced today that it will present new pre-clinical data on its RNA ...
-Collaboration includes licensing agreement option based on early-stage preclinical outcomes LONDON--(BUSINESS WIRE)--MiNA Therapeutics, the pioneer of small activating RNA (RNAa) therapeutics, today ...
Mina Therapeutics Ltd. has announced a research collaboration and licensing agreement option with Nippon Shinyaku Co. Ltd. for the discovery and potential development and commercialization of small ...
Please provide your email address to receive an email when new articles are posted on . A London-based biotech firm has announced a collaboration and licensing agreement with a Japanese pharmaceutical ...
Short double-stranded RNA duplexes are the triggers for post-transcriptional gene silencing and can also induce epigenetic silencing of genes at the level of transcription. A surprising new finding is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results